Safdari H, Mompeon B, Dubois J B, Gros C
Surg Neurol. 1985 Nov;24(5):490-7. doi: 10.1016/0090-3019(85)90262-9.
In a clinical trial, 10 patients with malignant gliomas underwent partial resection of their tumors and were treated by intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy. The drug was given at least 1 month after the completion of postoperative radiotherapy in total doses of 270-280 mg/m2 in two sessions separated by a 48-hour interval (the two sessions with interval were equal to one course). This therapy was repeated every 8-10 weeks. Four patients had three courses and the other six patients had two courses of chemotherapy. This therapy was the only antitumor chemotherapy for this group of patients. Our preliminary results demonstrate the safety of this new procedure and suggest that intraarterial BCNU chemotherapy may be more effective, and has a better tolerance and less toxicity, than intravenous BCNU chemotherapy. Furthermore, it was demonstrated that, in the case of one patient, higher antitumor activity resulted from intraarterial BCNU chemotherapy as compared to intravenous BCNU therapy.
在一项临床试验中，10例恶性胶质瘤患者接受了肿瘤部分切除术，并接受动脉内注射1,3-双（2-氯乙基）-1-亚硝基脲（卡莫司汀，BCNU）化疗。该药物在术后放疗结束至少1个月后给予，总剂量为270-280mg/m²，分两次给药，间隔48小时（间隔的两次给药相当于一个疗程）。每8-10周重复一次该治疗。4例患者接受了三个疗程，另外6例患者接受了两个疗程的化疗。该治疗是这组患者唯一的抗肿瘤化疗方法。我们的初步结果证明了这一新程序的安全性，并表明动脉内注射BCNU化疗可能比静脉注射BCNU化疗更有效，耐受性更好，毒性更小。此外，还证明，在1例患者中，与静脉注射BCNU治疗相比，动脉内注射BCNU化疗产生了更高的抗肿瘤活性。
